DDInter1544 DDInter1315
Prucalopride is a dihydrobenzofurancarboxamide derivative from the benzofurane family that selectively stimulates 5-HT4 receptors and thus, it presents enterokinetic properties. The high selectivity of prucalopride allowed further development as it prevented the cardiac adverse reactions observed due to non-target effects of precedent therapies. Prucalopride was developed by Shire Development LLC and approved for use in Europe in 2009, in Canada on December 7, 2011 and by the FDA on December 17, 2018.
Norgestrel is synthetic steroidal progestin that is used in combination with ethinyl estradiol for oral contraception. Norgestrel is composed of a racemic mixture of two stereoisomers, dextronorgestrel and levonorgestrel. However, only the levorotary enantiomer ([levonorgestrel]) is biologically active.
Norgestrel {u} may cause a minor interaction that can limit clinical effects when taken with {v} Pioglitazone
Norgestrel {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Linaclotide
Norgestrel {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Larotrectinib
Norgestrel {u} may lead to a major life threatening interaction when taken with {v} Griseofulvin
Norgestrel {u} may lead to a major life threatening interaction when taken with {v} Encorafenib
Norgestrel may cause a minor interaction that can limit clinical effects when taken with Pioglitazone
Norgestrel may cause a moderate interaction that could exacerbate diseases when taken with Linaclotide
Norgestrel may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Norgestrel may lead to a major life threatening interaction when taken with Griseofulvin
Norgestrel may lead to a major life threatening interaction when taken with Encorafenib